TRIGLYCERIDE-RICH AND CHOLESTEROL-RICH LIPOPROTEINS HAVE A DIFFERENTIAL EFFECT ON MILD/MODERATE AND SEVERE LESION PROGRESSION AS ASSESSED BY QUANTITATIVE CORONARY ANGIOGRAPHY IN A CONTROLLED TRIAL OF LOVASTATIN

被引:305
作者
HODIS, HN
MACK, WJ
AZEN, SP
ALAUPOVIC, P
POGODA, JM
LABREE, L
HEMPHILL, LC
KRAMSCH, DM
BLANKENHORN, DH
机构
[1] UNIV SO CALIF, SCH MED, DEPT MED, LOS ANGELES, CA 90033 USA
[2] UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA
[3] OKLAHOMA MED RES FDN, OKLAHOMA CITY, OK 73104 USA
关键词
APOLIPOPROTEINS; RISK FACTORS; CORONARY DISEASE;
D O I
10.1161/01.CIR.90.1.42
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The Monitored Atherosclerosis Regression Study, a randomized, double-blind, placebo-controlled, 2-year trial of lovastatin monotherapy, found that coronary lesions <50% diameter stenosis (%S) and coronary lesions greater than or equal to 50%S at baseline had different responses to therapy. We now report on clinical, lipid, and nonlipid risk factors of treatment response in these lesion subsets. Methods and Results Two hundred seventy subjects, 37 to 67 years old, with plasma total cholesterol (TC) 190 to 295 mg/dL (4.91 to 7.63 mmol/L) and total triglyceride <500 mg/dL (5.65 mmol/L) were randomized to low-fat, low-cholesterol diet and either lovastatin 80 mg/d or placebo. Logistic regression was used to model the association between risk factors and coronary lesion progression in mild/moderate (<50%S) and severe (greater than or equal to 50%S) lesions in 220 angiogram pairs analyzed by computer quantitative coronary angiography. In the placebo group, risk factors (P<.05) for the progression of mild/moderate lesions were triglycerides and TC/high-density lipoprotein cholesterol (HDL-C). Risk factors for the progression of severe lesions were HDL-C (negative), low-density lipoprotein cholesterol (LDL-C)/HDL-C, and TC/HDL-C. TC/HDL-C was the predominant risk factor for both mild/moderate and severe lesions in the multivariate analysis. In the lovastatin group, with aggressive lowering of LDL-C and TC below 85 mg/dL and 156 mg/dL, respectively, risk factors for mild/moderate lesions included triglycerides and very-low-density lipoprotein-LDL-associated apolipoprotein C-III (ape C-III-heparin precipitate), a marker of triglyceride-rich lipoprotein particles. Apo C-III-heparin precipitate was the predominant risk factor in the multivariate analysis. Risk factors for severe lesions were LDL-C, LDL-C/HDL-C, TC/HDL-C, and apo B; LDL-C/HDL-C was the predominant risk factor. Conclusions These results indicate that triglyceride-rich lipoproteins and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression, respectively. These results add to the growing evidence of the importance of triglyceride-rich lipoproteins as a risk factor for coronary artery disease and the need for treatment in the progression of atherosclerosis.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 28 条
[1]   DAVID RUBINSTEIN MEMORIAL LECTURE - THE BIOCHEMICAL AND CLINICAL-SIGNIFICANCE OF THE INTERRELATIONSHIP BETWEEN VERY LOW-DENSITY AND HIGH-DENSITY LIPOPROTEINS [J].
ALAUPOVIC, P .
CANADIAN JOURNAL OF BIOCHEMISTRY, 1981, 59 (08) :565-579
[2]  
ALAUPOVIC P, 1992, CIRCULATION, V86, P743
[3]   APOLIPOPROTEIN COMPOSITION AS THE BASIS FOR CLASSIFYING PLASMA-LIPOPROTEINS - CHARACTERIZATION OF APOA-CONTAINING AND APO-B-CONTAINING LIPOPROTEIN FAMILIES [J].
ALAUPOVIC, P .
PROGRESS IN LIPID RESEARCH, 1991, 30 (2-3) :105-138
[4]   DIET, LIPOPROTEINS, AND THE PROGRESSION OF CORONARY ATHEROSCLEROSIS - THE LEIDEN INTERVENTION TRIAL [J].
ARNTZENIUS, AC ;
KROMHOUT, D ;
BARTH, JD ;
REIBER, JHC ;
BRUSCHKE, AVG ;
BUIS, B ;
VANGENT, CM ;
KEMPENVOOGD, N ;
STRIKWERDA, S ;
VANDERVELDE, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (13) :805-811
[5]   PLASMA TRIGLYCERIDE AND CORONARY HEART-DISEASE [J].
AUSTIN, MA .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01) :2-14
[6]   CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].
BLANKENHORN, DH ;
AZEN, SP ;
KRAMSCH, DM ;
MACK, WJ ;
CASHINHEMPHILL, L ;
HODIS, HN ;
DEBOER, LWV ;
MAHRER, PR ;
MASTELLER, MJ ;
VAILAS, LI ;
ALAUPOVIC, P ;
HIRSCH, LJ .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976
[7]   PREDICTION OF ANGIOGRAPHIC CHANGE IN NATIVE HUMAN CORONARY-ARTERIES AND AORTOCORONARY BYPASS GRAFTS - LIPID AND NONLIPID FACTORS [J].
BLANKENHORN, DH ;
ALAUPOVIC, P ;
WICKHAM, E ;
CHIN, HP ;
AZEN, SP .
CIRCULATION, 1990, 81 (02) :470-476
[8]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[9]   EFFECTS OF THERAPY WITH CHOLESTYRAMINE ON PROGRESSION OF CORONARY ARTERIOSCLEROSIS - RESULTS OF THE NHLBI TYPE-II CORONARY INTERVENTION STUDY [J].
BRENSIKE, JF ;
LEVY, RI ;
KELSEY, SF ;
PASSAMANI, ER ;
RICHARDSON, JM ;
LOH, IK ;
STONE, NJ ;
ALDRICH, RF ;
BATTAGLINI, JW ;
MORIARTY, DJ ;
FISHER, MR ;
FRIEDMAN, L ;
FRIEDEWALD, W ;
DETRE, KM ;
EPSTEIN, SE .
CIRCULATION, 1984, 69 (02) :313-324
[10]   LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE [J].
BROWN, BG ;
ZHAO, XQ ;
SACCO, DE ;
ALBERS, JJ .
CIRCULATION, 1993, 87 (06) :1781-1791